Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: Long-term follow-up

G. S. Letterie, C. C. Coddington, C. A. Winkel, T. H. Shawker, Donald (Lynn) Loriaux, R. L. Collins

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The authors employed a gonadotropin-releasing hormone agonist (GnRH-a)(D-His6-pro9-NET-GnRH) to treat 19 patients with symptomatic uterine leiomyomata, by daily subcutaneous injections (4 μg/kg) for 6 months. After therapy, patients were followed for 6 months without any therapy. Uterine volumes were measured by serial pelvic examinations and pelvic sonography. Measurements of serum estradiol, luteinizing hormone, and follicle-stimulating hormone were used to assess treatment response. Pituitary desensitization and hypoestrogenemia were achieved in all within 8 weeks, and in 18 of 19, hypoestrogenemia was maintained for the duration. Uterine volume at the conclusion of therapy (207.5 ± 152.7 ml) was significantly reduced in all patients when compared with pretreatment sizes (420.8 ± 276.4, P <0.05). Side effects included hot flashes (78%), vaginal dryness (32%), and transient frontal headaches (55%). All patients reported partial or complete relief from their symptomatic leiomyomata. Uterine volume at the conclusion of follow-up (345.4 ± 195.7 ml) was greateR than at the conclusion of therapy. Menses resumed in all patients within 4 to 8 weeks. In conclusion, GnRH-a therapy does not provide definitive therapy for symptomatic uterine leiomyomata but is effective in reducing the size of leiomyomata as a temporary measure. Gonadotropin-releasing hormone agonist therapy may be useful as an adjunct before myomectomy or hysterectomy and deserves further investigation.

Original languageEnglish (US)
Pages (from-to)951-956
Number of pages6
JournalFertility and Sterility
Volume51
Issue number6
StatePublished - 1989
Externally publishedYes

Fingerprint

Leiomyoma
Gonadotropin-Releasing Hormone
Therapeutics
Uterine Myomectomy
Hot Flashes
Gynecological Examination
Menstruation
Follicle Stimulating Hormone
Subcutaneous Injections
Luteinizing Hormone
Hysterectomy
Headache
Estradiol
Ultrasonography
Serum

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Letterie, G. S., Coddington, C. C., Winkel, C. A., Shawker, T. H., Loriaux, D. L., & Collins, R. L. (1989). Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: Long-term follow-up. Fertility and Sterility, 51(6), 951-956.

Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata : Long-term follow-up. / Letterie, G. S.; Coddington, C. C.; Winkel, C. A.; Shawker, T. H.; Loriaux, Donald (Lynn); Collins, R. L.

In: Fertility and Sterility, Vol. 51, No. 6, 1989, p. 951-956.

Research output: Contribution to journalArticle

Letterie, GS, Coddington, CC, Winkel, CA, Shawker, TH, Loriaux, DL & Collins, RL 1989, 'Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: Long-term follow-up', Fertility and Sterility, vol. 51, no. 6, pp. 951-956.
Letterie, G. S. ; Coddington, C. C. ; Winkel, C. A. ; Shawker, T. H. ; Loriaux, Donald (Lynn) ; Collins, R. L. / Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata : Long-term follow-up. In: Fertility and Sterility. 1989 ; Vol. 51, No. 6. pp. 951-956.
@article{39cb8a129a29432ebce533db4312838c,
title = "Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: Long-term follow-up",
abstract = "The authors employed a gonadotropin-releasing hormone agonist (GnRH-a)(D-His6-pro9-NET-GnRH) to treat 19 patients with symptomatic uterine leiomyomata, by daily subcutaneous injections (4 μg/kg) for 6 months. After therapy, patients were followed for 6 months without any therapy. Uterine volumes were measured by serial pelvic examinations and pelvic sonography. Measurements of serum estradiol, luteinizing hormone, and follicle-stimulating hormone were used to assess treatment response. Pituitary desensitization and hypoestrogenemia were achieved in all within 8 weeks, and in 18 of 19, hypoestrogenemia was maintained for the duration. Uterine volume at the conclusion of therapy (207.5 ± 152.7 ml) was significantly reduced in all patients when compared with pretreatment sizes (420.8 ± 276.4, P <0.05). Side effects included hot flashes (78{\%}), vaginal dryness (32{\%}), and transient frontal headaches (55{\%}). All patients reported partial or complete relief from their symptomatic leiomyomata. Uterine volume at the conclusion of follow-up (345.4 ± 195.7 ml) was greateR than at the conclusion of therapy. Menses resumed in all patients within 4 to 8 weeks. In conclusion, GnRH-a therapy does not provide definitive therapy for symptomatic uterine leiomyomata but is effective in reducing the size of leiomyomata as a temporary measure. Gonadotropin-releasing hormone agonist therapy may be useful as an adjunct before myomectomy or hysterectomy and deserves further investigation.",
author = "Letterie, {G. S.} and Coddington, {C. C.} and Winkel, {C. A.} and Shawker, {T. H.} and Loriaux, {Donald (Lynn)} and Collins, {R. L.}",
year = "1989",
language = "English (US)",
volume = "51",
pages = "951--956",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata

T2 - Long-term follow-up

AU - Letterie, G. S.

AU - Coddington, C. C.

AU - Winkel, C. A.

AU - Shawker, T. H.

AU - Loriaux, Donald (Lynn)

AU - Collins, R. L.

PY - 1989

Y1 - 1989

N2 - The authors employed a gonadotropin-releasing hormone agonist (GnRH-a)(D-His6-pro9-NET-GnRH) to treat 19 patients with symptomatic uterine leiomyomata, by daily subcutaneous injections (4 μg/kg) for 6 months. After therapy, patients were followed for 6 months without any therapy. Uterine volumes were measured by serial pelvic examinations and pelvic sonography. Measurements of serum estradiol, luteinizing hormone, and follicle-stimulating hormone were used to assess treatment response. Pituitary desensitization and hypoestrogenemia were achieved in all within 8 weeks, and in 18 of 19, hypoestrogenemia was maintained for the duration. Uterine volume at the conclusion of therapy (207.5 ± 152.7 ml) was significantly reduced in all patients when compared with pretreatment sizes (420.8 ± 276.4, P <0.05). Side effects included hot flashes (78%), vaginal dryness (32%), and transient frontal headaches (55%). All patients reported partial or complete relief from their symptomatic leiomyomata. Uterine volume at the conclusion of follow-up (345.4 ± 195.7 ml) was greateR than at the conclusion of therapy. Menses resumed in all patients within 4 to 8 weeks. In conclusion, GnRH-a therapy does not provide definitive therapy for symptomatic uterine leiomyomata but is effective in reducing the size of leiomyomata as a temporary measure. Gonadotropin-releasing hormone agonist therapy may be useful as an adjunct before myomectomy or hysterectomy and deserves further investigation.

AB - The authors employed a gonadotropin-releasing hormone agonist (GnRH-a)(D-His6-pro9-NET-GnRH) to treat 19 patients with symptomatic uterine leiomyomata, by daily subcutaneous injections (4 μg/kg) for 6 months. After therapy, patients were followed for 6 months without any therapy. Uterine volumes were measured by serial pelvic examinations and pelvic sonography. Measurements of serum estradiol, luteinizing hormone, and follicle-stimulating hormone were used to assess treatment response. Pituitary desensitization and hypoestrogenemia were achieved in all within 8 weeks, and in 18 of 19, hypoestrogenemia was maintained for the duration. Uterine volume at the conclusion of therapy (207.5 ± 152.7 ml) was significantly reduced in all patients when compared with pretreatment sizes (420.8 ± 276.4, P <0.05). Side effects included hot flashes (78%), vaginal dryness (32%), and transient frontal headaches (55%). All patients reported partial or complete relief from their symptomatic leiomyomata. Uterine volume at the conclusion of follow-up (345.4 ± 195.7 ml) was greateR than at the conclusion of therapy. Menses resumed in all patients within 4 to 8 weeks. In conclusion, GnRH-a therapy does not provide definitive therapy for symptomatic uterine leiomyomata but is effective in reducing the size of leiomyomata as a temporary measure. Gonadotropin-releasing hormone agonist therapy may be useful as an adjunct before myomectomy or hysterectomy and deserves further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0024359826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024359826&partnerID=8YFLogxK

M3 - Article

C2 - 2498132

AN - SCOPUS:0024359826

VL - 51

SP - 951

EP - 956

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 6

ER -